- Home
- JPI vs SLP Comparison
JPI vs SLP Comparison
Compare JPI & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- SLP
- Stock Information
- Founded
- JPI 2012
- SLP 1996
- Country
- JPI United States
- SLP United States
- Employees
- JPI N/A
- SLP N/A
- Industry
- JPI Finance Companies
- SLP EDP Services
- Sector
- JPI Finance
- SLP Technology
- Exchange
- JPI Nasdaq
- SLP Nasdaq
- Market Cap
- JPI 288.1M
- SLP 282.4M
- IPO Year
- JPI N/A
- SLP 1997
- Fundamental
- Price
- JPI $20.70
- SLP $15.05
- Analyst Decision
- JPI
- SLP Buy
- Analyst Count
- JPI 0
- SLP 7
- Target Price
- JPI N/A
- SLP $29.50
- AVG Volume (30 Days)
- JPI 54.7K
- SLP 388.2K
- Earning Date
- JPI 01-01-0001
- SLP 10-22-2025
- Dividend Yield
- JPI 6.15%
- SLP N/A
- EPS Growth
- JPI N/A
- SLP N/A
- EPS
- JPI N/A
- SLP N/A
- Revenue
- JPI N/A
- SLP $80,383,000.00
- Revenue This Year
- JPI N/A
- SLP $12.75
- Revenue Next Year
- JPI N/A
- SLP $3.06
- P/E Ratio
- JPI N/A
- SLP N/A
- Revenue Growth
- JPI N/A
- SLP 20.01
- 52 Week Low
- JPI $16.02
- SLP $12.39
- 52 Week High
- JPI $19.12
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- JPI 66.91
- SLP 58.45
- Support Level
- JPI $20.15
- SLP $13.78
- Resistance Level
- JPI $20.70
- SLP $14.46
- Average True Range (ATR)
- JPI 0.15
- SLP 0.53
- MACD
- JPI 0.05
- SLP 0.13
- Stochastic Oscillator
- JPI 93.22
- SLP 99.16
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.